Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Vaccines of the 21st Century

University of Toronto

$99,252.00

Discovery of new B cell immunogens for HIV vaccines

EF 2008-09

Résumé
Over 33 million individuals worldwide are infected with the Human Immunodeficiency Virus Type-1 (HIV-1), and yet there is no effective vaccine to prevent HIV-1 infection. The recent failure of the Merck vaccine, which was designed to elicit a type of immune response, called a killer T cell (or CTL) response resulted in no protection and even enhanced infection rates in volunteers, thus highlighting the challenges of HIV-1 vaccine development. Most successful vaccines that have been developed against viruses have been shown to induce another type of immune response after vaccination, called a neutralizing antibody response. The development of neutralizing antibodies with an HIV-1 vaccine has been one of the largest challenges in HIV-1 vaccine development. To date, no vaccine can induce antibodies that can neutralize a large variety of HIV-1 viruses circulating in the population. Part of the problem is due to the very nature of the surface protein of HIV-1, HIV-1 envelope. The HIV-1 envelope when given as a vaccine induced very poor neutralizing antibody responses. There are a number of molecules, called CD40L, BAFF or APRIL that have been shown to stimulate immune responses that make stronger antibodies. The current proposal will evaluate the construction of new HIV-1 envelope vaccines where we have combined these immune molecules with the HIV-1 envelope protein. We will test whether these new vaccines can stimulate the neutralizing antibody response more strongly. If we are successful these studies will lay the groundwork for developing a better vaccine against HIV-1.
Programme
Vaccines of the 21st Century
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
183456
Name
Ostrowski Mario A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Catalyst Grant: Vaccines of the 21st Century
Projecttitle
Discovery of new B cell immunogens for HIV vaccines
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$99,252
Cihrequipment2
$0
Programname2
Vaccines of the 21st Century
Keyworddelim
Antibody; B Cells; Hiv; Immune Adjuvant; Tumor Necrosis Factor Superfamily; Vaccines
Abstract
Over 33 million individuals worldwide are infected with the Human Immunodeficiency Virus Type-1 (HIV-1), and yet there is no effective vaccine to prevent HIV-1 infection. The recent failure of the Merck vaccine, which was designed to elicit a type of immune response, called a killer T cell (or CTL) response resulted in no protection and even enhanced infection rates in volunteers, thus highlighting the challenges of HIV-1 vaccine development. Most successful vaccines that have been developed against viruses have been shown to induce another type of immune response after vaccination, called a neutralizing antibody response. The development of neutralizing antibodies with an HIV-1 vaccine has been one of the largest challenges in HIV-1 vaccine development. To date, no vaccine can induce antibodies that can neutralize a large variety of HIV-1 viruses circulating in the population. Part of the problem is due to the very nature of the surface protein of HIV-1, HIV-1 envelope. The HIV-1 envelope when given as a vaccine induced very poor neutralizing antibody responses. There are a number of molecules, called CD40L, BAFF or APRIL that have been shown to stimulate immune responses that make stronger antibodies. The current proposal will evaluate the construction of new HIV-1 envelope vaccines where we have combined these immune molecules with the HIV-1 envelope protein. We will test whether these new vaccines can stimulate the neutralizing antibody response more strongly. If we are successful these studies will lay the groundwork for developing a better vaccine against HIV-1.
Competitiondate
200903
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ostrowski, Mario A
Approvedterm
1 an 0 mois
Cihrcontribution2
Science Policy 4~ $99,252~ $0~